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Summary
 Phytochemicals are used often in vitro and in vivo in cancer research. The plant hor-
mones jasmonates (JAs) control the synthesis of specialized metabolites through complex
regulatory networks. JAs possess selective cytotoxicity in mixed populations of cancer and
normal cells.
 Here, direct incubation of leaf explants from the non-medicinal plant Arabidopsis thaliana
with human breast cancer cells, selectively suppresses cancer cell growth. High-throughput
LC-MS identified Arabidopsis metabolites. Protein and transcript levels of cell cycle regulators
were examined in breast cancer cells.
 A synergistic effect by methyljasmonate (MeJA) and by compounds upregulated in the
metabolome of MeJA-treated Arabidopsis leaves, on the breast cancer cell cycle, is associated
with Cell Division Cycle 6 (CDC6), Cyclin-dependent kinase 2 (CDK2), Cyclins D1 and D3, indi-
cating that key cell cycle components mediate cell viability reduction. Bioactives such as indoles,
quinolines and cis-(+)-12-oxophytodienoic acid, in synergy, could act as anticancer compounds.
 Our work suggests a universal role for MeJA-treatment of Arabidopsis in altering the DNA
replication regulator CDC6, supporting conservation, across kingdoms, of cell cycle regula-
tion, through the crosstalk between the mechanistic target of rapamycin, mTOR, and JAs.
This study has important implications for the identification of metabolites with anti-cancer
bioactivities in plants with no known medicinal pedigree and it will have applications in devel-
oping disease treatments
Introduction
Plants produce many small molecules used as pharmaceuticals,
insecticides, flavours and fragrances with commercial applications
which derive from their common use in defence against biotic
challenges (Perez-Salamo et al., 2019).
The ubiquitous plant stress hormone jasmonic acid (JA) and
its oxylipin derivatives, such as methyljasmonate (MeJA) and jas-
monate isoleucin (JA-Ile), namely jasmonates (JAs) here, are
potent regulators of plant defence, response to abiotic stress and
developmental processes (Kazan, 2015; Riemann et al., 2015;
Z€ust & Agrawal, 2017; Guo et al., 2018; Howe et al., 2018;
Perez-Salamo et al., 2019). Environmental pressures induce
endogenous JAs biosynthesis. JA signalling triggers complex
responses in plant cells, including massive transcriptional and
metabolic reprogramming, and defence proteins and protective
specialized metabolites biosynthesis (Balbi & Devoto, 2008;
Pauwels et al., 2009; Noir et al., 2013; Wasternack & Hause,
2013; B€omer et al., 2018; Perez-Salamo et al., 2019).
Jasmonates control specialized metabolites synthesis through
complex gene regulatory networks to limit it to when necessary.
JAs induce most classes of specialized metabolites, including alka-
loids, terpenoids, glucosinolates and some phenylpropanoids
(Balbi & Devoto, 2008; Zhou & Memelink, 2016; Perez-Salamo
et al., 2019). The precursor of JA, cis-(+)-12-oxophytodienoic
acid (OPDA), also induces JA-independent specialized metabo-
lites (Wasternack & Hause, 2013). Primary and secondary sul-
fur-related pathways leading to the synthesis of glucosinolates,
have been shown to be MeJA-responsive in Arabidopsis (Jost
et al., 2005). Moreover the production of several agricultural and
medicinal compounds, including glucosinolates, occurs through
tryptophan metabolism (Smolen et al., 2002). The cabbage
(Brassica) family, which includes Arabidopsis thaliana, is a rich
source of glucosinolates and most biological activities for these in*These authors contributed equally to this work.
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both plants and animals, reside with their cognate hydrolytic
products. The isothiocyanates, such as sulforaphane, are out-
standing examples (Dinkova-Kostova & Kostov, 2012).
Humans have long used plant-derived specialized metabolites as
phytopharmaceuticals. Many phytochemicals have been identified
as bioactive, including the prominent JA-induced anticancer drug,
taxol (Baldi & Dixit, 2008). Fingrut & Flescher (2002) showed
that JAs are potential anticancer agents (Fingrut & Flescher,
2002). JAs showed selective cytotoxicity in mixed populations of
cancer and normal cells from chronic lymphocytic leukaemia
patients (Fingrut & Flescher, 2002; Flescher, 2007). MeJA-in-
duced apoptotic death in cancer cells and the survival rates of mice
bearing lymphoma were higher following MeJA treatment (Fin-
grut & Flescher, 2002). JAs and synthetic analogues exhibit anti-
cancer activity in human breast, cervix, colon, colorectal, gastric,
hepatoma, lung, lymphoma, melanoma, myeloid leukaemia, neu-
roblastoma, prostate and sarcoma cancer cells (Balbi & Devoto,
2008; Cesari et al., 2014; Perez-Salamo et al., 2019).
Three different mechanisms of action – bioenergetic, re-differ-
entiation and reactive oxygen species (ROS)-mediated mecha-
nisms – were proposed to explain the activity of JAs against
cancer cells (Flescher, 2007). MeJA has powerful anticancer activ-
ities both in vitro and in vivo (Fingrut & Flescher, 2002; Rotem
et al., 2003; Fingrut et al., 2005; Flescher, 2007; Cohen &
Flescher, 2009; Elia & Flescher, 2013; Li et al., 2017; Peng &
Zhang, 2017). JAs induce both apoptotic and nonapoptotic
cancer cell death, independent of their p53 status, acting directly
and selectively on mitochondria in cancer cells (Fingrut et al.,
2005; Rotem et al., 2005). MeJA causes bioenergetic dysregula-
tion and cell cycle arrest in different cancer cell types (Rotem
et al., 2005; Li et al., 2017). MeJA treatment causes G0/G1 and
S-phase arrest and induces apoptosis by increasing expression of
tumour necrosis factor receptor 1 (TNFR1), activation of mito-
gen-activated protein kinase (MAPK) and caspase-8, and decreas-
ing the mitochondrial membrane potential in MCF-7 breast
cancer cells (Yeruva et al., 2008). In non-small cell lung cancer
cells, MeJA induces apoptosis (Zhang et al., 2016) and exerts its
anticancer activity through downregulation of enhancer of zeste 2
polycomb repressive complex 2 subunit (EZH2), a histone
methyltransferase, and the catalytic subunit of polycomb repres-
sive complex 2 (PRC2) (Fu et al., 2014). Taken together, these
findings suggest that some of MeJA’s anticancer activities are
mediated by compounds upregulated by MeJA, although so far,
the mechanisms of action of JAs and their induced metabolites
on cancer cells, have never been compared.
Here, direct incubation of leaf explants of the nonmedicinal
plant Arabidopsis thaliana with human breast cancer cells is estab-
lished in a bioassay comparing the efficacy of JA-regulated, special-
ized metabolites and MeJA on breast cancer cell lines. Metabolite
extracts derived directly from the bioassay, including media and
cancer cell controls, as well as wild-type and mutant plants, proved
to be effective in the search for plant-derived, JA-induced special-
ized metabolites with anticancer activities. This system demon-
strated consistently, the biological activity of plant material
subjected to JA treatment on the growth inhibition of breast cancer
cells. Arabidopsis mutants allowed dissection of the plant
mechanisms controlling these bioactivities. The bioactivity of
MeJA-treated, Arabidopsis leaf samples on the growth of breast
cancer cells was Coronatine-insensitive protein 1 (COI1)-depen-
dent and mediated by JA-induced plant-derived specialized
metabolites such as indoles, quinolines and OPDA. The inhibitory
effect was far superior to that of MeJA alone. Clustering and in
silico identification of plant-derived MeJA-induced and COI1-de-
pendent metabolic features showed that the effects on breast
cancers cells are unlikely to be ascribed to individual features and
that cancer cells metabolism affects bioactivity. We showed that
the post-translational downregulation of CDC6, CDK2, Cyclin
D1 and Cyclin D3 is part of the mechanism to reduce breast
cancer cell viability. Our analysis supports conservation, across
kingdoms, of the regulation of the cell cycle through crosstalk
between the mechanistic target of rapamycin, mTOR and JAs.
Materials and Methods
Plant leaf disk bioassay using human breast cancer cells
The antiproliferative effect of Arabidopsis plants aged 11 d after
sowing (DAS) 50 µM methyljasmonate (MeJA) for 24 h was
evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT) cell viability assay.
MDA-MB-361, T-47D and MCF-10A were seeded in 96-well
plates with 15 000 cells per well in a final volume of 100 µl
medium, and were left to set overnight. After 24 h, 39 1 mm (di-
ameter) leaf disks excised from the first pair of true leaves were
added aseptically to each well using a 1-mm Sample corer
(InterFocus, Cambridge, UK) and co-incubated with the cells for
72 h. Relative quantification of the cell proliferation of the human
breast cancer cell lines T-47D and MDA-MB-361 and the nontu-
mourigenic cell line MCF-10A was assessed by MTT assay. For all
treatments, the leaf disks and culture media were removed after the
72 h incubation period and the MTT reagent was added to the
wells in fresh medium. The cytotoxic effects of MeJA on the cells
were evaluated using a trypan blue inclusion assay.
Western blotting
Total protein was extracted from the cell pellets using the
NucleoSpin RNA/Protein Kit (Macherey-Nagel, Dueren, Ger-
many), and concentration determined using the Protein Quan-
tification Assay Kit (Macherey-Nagel) and a microplate
photometer (Multiskan EX, Thermo Scientific, Waltham, MA,
USA). Equal amounts of protein (10 lg) were resolved by SDS-
PAGE. Band intensity, mirroring protein levels were visualized
using chemiluminescence detection systems Supersignal West
Pico (Thermo Scientific) or Substrat HRP Immobilon Western
(Merck Millipore) following the manufacturers’ instructions.
Cell cycle analysis
Ploidy levels were determined by flow cytometry using a Ploidy
Analyser PAS (Sysmex Partec GmbH, M€unster, Germany), with
UV excitation at 366 nm from a mercury arc lamp. Nuclei were
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released using Cystain extraction buffer, filtered through a Cell
trics filter and stained with Cystain fluorescent buffer (Partec). At
least fifteen thousand nuclei were used for each ploidy measure-
ment and the percentages of cells in the different phases of the
cell cycle was calculated.
Quantitative real-time (qRT)-PCR
Analysis of total RNA yield was performed on a nanodrop spec-
trophotometer (Labtech, Heathfield, UK). cDNA preparation
was performed using the QuantiTect Reverse Transcription kit
(Qiagen). Real-time amplification was performed using SYBR
Green JumpStart (Sigma-Aldrich) according to the manufac-
turer’s instructions. Transcript analysis was performed from
RNA samples derived from at least five independent experiments.
The primer sequences are listed in Supporting Information
Table S1.
Metabolite profiling by LC-MS/MS
Metabolite profiling was performed using a QToF (Quadrupole
Time of Flight) 6520 mass spectrometer (Agilent Technologies,
Palo Alto, CA, USA) coupled to a 1200 series Rapid Resolution
HPLC system.
Data extraction and processing
The raw data files (Agilent *.d) of leaf disc-containing samples
were processed with MASS PROFILER (v.B.08.00; Agilent) to
extract features of interest (FOIs) using the built-in molecular
feature extraction algorithm. Differentially expressed features
were identified by three-way ANOVA (P < 0.05) using the Ben-
jamini–Hochberg multiple comparison correction. This list was
used for cluster and heat map generation. To lead the discovery
of jasmonic acid (JA)-regulated specialized metabolites with
potential in inhibiting human breast cancer cell growth, we ran
linear regression models on the normalized (zero mean and unit
variance) log2-transformed abundances of each metabolite (total
of 1757) with subsequent tests of a priori defined treatment con-
trasts (Hothorn et al., 2008). These tests served as filtering condi-
tions and metabolites that met them, were aggregated into
corresponding sets (Table 1). All tests were performed with a sig-
nificance level of P = 0.05.
For further analysis, including medium only and medium plus
T-47D cells, the raw data files were aligned and subjected to
recursive molecular feature extraction using PROFINDER
(v.B.10.00; Agilent Technologies, Santa Clara, CA, USA). The
resulting set of compounds were exported to MASSPROFILER PRO-
FESSIONAL (Agilent Technologies) and analyzed to identify plant-
specific and MeJA-induced features.
Where available, MS/MS spectra of FOIs were extracted from
raw data files using MASSHUNTER QUALITATIVE ANALYSIS software
(v.B07.00; Agilent Technologies) and compared with MS/MS
data from METLIN and MASSBANK to provide putative identifica-
tions. The identification of JA and cis-(+)-12-oxophytodienoic
acid (OPDA) was further confirmed by comparison of retention
time and spectra with standards. The stereoisomers of these com-
pounds were not resolved by the chromatographic method used.
Predicted MS/MS spectra were generated with the METFRAG tool
(https://msbi.ipb-halle.de/MetFrag) (Ruttkies et al., 2016).
Table 1 A priori defined contrasts used as filtering conditions for the discovery of metabolites inhibiting breast cell cancer growth.





Col gl1 +MeJA >Col gl1 MeJA T-47D A1 236 73 41a
Col gl1 +MeJA >Col gl1 MeJA No cell control A2 134
Col gl1 +MeJA > coi1-16B +MeJA T-47D B1 427 262
Col gl1 +MeJA > coi1-16B +MeJA No cell control B2 341
Col gl1 MeJA = coi1-16B MeJA T-47D C1* 1188 1040
Col gl1 MeJA = coi1-16B MeJA No cell control C2* 1251
coi1-16B +MeJA > coi1-16B MeJA T-47D D1 110 30 10b
coi1-16B +MeJA > coi1-16B MeJA No cell control D2 78
coi1-16B +MeJA >Col gl1 +MeJA T-47D E1 345 207
coi1-16B +MeJA >Col gl1 +MeJA No cell control E2 268
Col gl1 MeJA +T-47D >Col gl1 MeJA T-47D F1 264 187 117c
Col gl1 +MeJA +T-47D >Col gl1 +MeJA T-47D F2 292
coi1-16B MeJA +T-47D > coi1-16B MeJA T-47D F3 251 192
coi1-16B +MeJA +T-47D > coi1-16B +MeJA T-47D F4 277
Col gl1 MeJA +T-47D <Col gl1 MeJA T-47D G1 298 141 98d
Col gl1 +MeJA +T-47D <Col gl1 +MeJA T-47D G2 250
coi1-16B MeJA +T-47D < coi1-16B MeJA T-47D G3 350 247
coi1-16B +MeJA +T-47D < coi1-16B +MeJA T-47D G4 292
COI1, Coronatine-insensitive protein 1; Col GL1, Trichome differentiation protein (WT); MeJA, methyljasmonate.
aCOI1-dependent MeJA-induced in Col gl1.
bMeJA-induced in coi1-16B.
cMore abundant in T-47D background (end- or by-products of T-47D metabolism).
dLess abundant or absent in T-47D background (metabolized cancer cell media).
*Metabolites in sets C1 and C2 met the condition if metabolite abundances were not significantly different at P = 0.05.
 2020 The Authors





The data integral to the paper (fully documented LC-MS/MS
analysis) is available through https://royalholloway.figshare.com/,
doi: 10.17637/rh.13079153.
For further details and information on plant materials, human
breast cancer cell lines, treatment, antibodies and analysis, see
Supporting Information Methods S1.
Results
Methyljasmonate inhibits the growth of breast cancer but
not that of nontumorigenic cells
The activity of MeJA was compared in human breast cancer cell
lines T-47D and MDA-MB-361, with the nontumourigenic
mammary cell line MCF10A (Fig. 1a). Both T-47D and MDA-
MB-361 cell lines are ductal and oestrogen receptor (ER) positive
with MDA-MB-361 expressing HER2 (Keydar et al., 1979). Pre-
viously, low or no JA-induced cytotoxicity in healthy cells were
reported (Fingrut & Flescher, 2002; Rotem et al., 2003, 2005;
Reischer et al., 2007; Tong et al., 2008).
Relative quantification of cell numbers, in response to increasing
MeJA concentrations (according to Cesari et al., 2014) was
assessed, and dose–response curves obtained. Concentrations of
200 µM and 2mM MeJA significantly inhibited T-47D cells
growth. MDA-MB-361 cell growth also was significantly sup-
pressed at 2 mM MeJA, but less than T-47D (relative cell number
(RCN) 78% and 47%, respectively). The leaf disks and culture
media were removed after the 72 h incubation period and the
MTT reagent was added to the wells in fresh medium to avoid
interference of any compound released by the leaf explants or
MeJA that could have led to the reduction of MTT to formazan
(through differential regulation of enzyme activity). The effects
seen are therefore a direct result of changes in cell number rather
than in enzyme activity. The dose–response curves were used to
calculate the half maximal inhibition concentration (IC50) values
and these were determined as 1.87, 4.44 and 5.14mM for T-47D,
MDA-MB-361 and MCF-10A, respectively.
The effect of MeJA on cell cycle progression was determined
by flow cytometry: treatment resulted in T-47D cell cycle arrest
in G0/G1 (Fig. S1B–E). Nontumourigenic MCF-10A cells were
not significantly affected by MeJA or treated Arabidopsis
(Figs 1a, S1A–E). Cell death also was only mildly affected at con-
centrations ≥ 200 µM (Fig. S1A), demonstrating that MeJA had
more profound effects on survival of the tumour cell lines.
A bioassay of activity of leaf disks on different breast
cancer and nontumorigenic cell types
We assayed the effects of MeJA treatment of Arabidopsis leaves
before explants were taken, on the growth of breast cancer cells
T47-D and MDA-MB361, and on nontumourigenic MCF10-A.
Arabidopsis thaliana mutants impaired in JA biosynthesis or sig-
nal perception were tested (Fig. 1b–d): the coi1-16B mutant for
the JA receptor Coronatine-insensitive protein 1 (COI1), dis-
playing a JA-insensitive phenotype (Ellis & Turner, 2002; West-
phal et al., 2008; Noir et al., 2013); the transgenic COI1
overexpressor (COV99), overexpressing line the JA receptor
COI1 (Devoto et al., 2002; B€omer et al., 2018); the
CONSTITUTIVE EXPRESSION OF VSP1 (cev), with higher
concentrations of JAs (Ellis & Turner, 2001); and the allene
oxide synthase (aos) knock-out mutant, defective in the JA
biosynthetic gene CYP74A (AOS) (Park et al., 2002), unable to
produce JAs but capable of JA responses. All JA mutants except
for coi1-16B showed a clear phenotypic response to the 24 h
MeJA treatment including some visible effects on the growth
(Fig. 1b), previously associated with JA treatment (Shan et al.,
2009; Noir et al., 2013). The effectiveness of the JA treatment
also was confirmed through the expression of JA-responsive genes
such as Vegetative storage protein (VSP) 1 and 2 and AOS (data
not shown). T-47D cells, treated with MeJA or wild-type (WT)
Arabidopsis were observed under bright-field microscopy
(Fig. S2). Incubation with untreated leaf disks visibly decreased
cell density, inducing rounder morphology and increasing float-
ing debris. These changes were consistent with increased cell
death (Fig. S1A).
The use of a bioassay originally devised to analyze chemopre-
ventive glucosinolates in murine hepatoma cells (Wang et al.,
2002), was extended to human cancer cell lines and further mod-
ified to test cell viability with MTT. Direct analysis of the effects
of single leaf disks from the Arabidopsis Col trichome
differentiation protein (gl1) (WT) or mutants was performed
(Fig. 1c). Suppression of tumour cell growth was consistently the
strongest when cells were co-incubated with MeJA-treated plant
samples compared to the untreated control plant disks, except for
coi1-16B (Fig. 1d). Arabidopsis explants treated with 50 µM
MeJA showed an inhibitory effect comparable to the treatment
with the highest (mM) concentrations of MeJA (Fig. 1a,d). Both
T-47D and MDA-MB-361 cancer cell lines showed comparable
responses (Fig. 1d). RCN inhibition values for MeJA-treated
plant leaf samples compared to the untreated controls are shown
in Table S2. The growth of T-47D was reduced to 68% RCN
when exposed to untreated WT disks, but was significantly more
reduced (36% RCN, P < 0.001) when exposed to MeJA-treated
disks (Fig. 1d). This compares to 68% and 33% RCN (respec-
tively) for MDA-MB-361 cells. Mutant aos reduced the cell
growth of T-47D to 71% and 47% RCN for untreated and
MeJA-treated plant leaf disks, respectively. This compares to
92% and 50% RCN (respectively) for MDA-MB-361 cells
(Table S2). The aos RCN inhibition values of 33% for T-47D
and 46% for MDA-MB-361 cells were slightly, but not signifi-
cantly, lower when compared to WT (Table S2). A WT-like
effect was exerted by COV99 samples with 69% and 41% RCN
for untreated and treated disks (respectively) when testing T-47D
cells, and 80% and 40% (respectively) for MDA-MB-361. The
inhibition of both breast cancer cell lines by cev1 untreated and
treated leaf disks was higher than that caused by WT. RCN val-
ues reached 46% and 20%, and 59% and 17% for untreated and
treated samples when testing T-47D and MDA-MB-361 cells,
respectively. Consequently, inhibition values of cev1 samples also
were found to be higher compared to WT samples (Table S2),
consistent with the presence of elevated concentrations of
endogenous JAs. For all plant samples tested, co-incubation with
New Phytologist (2020)  2020 The Authors




excised leaf disks resulted in significantly lower RCN values when
testing the growth of T-47D and MDA-MB-361 cancer cells.
Remarkably, the growth of nontumourigenic MCF-10A cells was
not significantly affected, except for MeJA-treated cev1, which
has constitutive JA responses (Ellis & Turner, 2001).
The differential effect between MeJA-treated and untreated
plant samples was significant for all Arabidopsis mutant lines
tested except for coi1-16B (Fig. 1d). MeJA-treated coi1-16B sam-
ples did not reduce the cell growth of either cancer cell line fur-
ther when compared to the untreated coi1-16B controls, showing
that the observed differential effect between MeJA-treated and
untreated leaf samples on the breast cancer cell growth was
COI1-dependent, as reflected in significantly lower inhibition
values compared to the Col gl1 WT (Table S2). We also tested
the effect of Arabidopsis mutants impaired in glucosinolates or
tryptophan metabolism (Bender & Fink, 1998; Barth & Jander,
2006; Bednarek et al., 2009) on T47-D and MCF10A cells
(Fig. S3; Table S2). These mutants showed no obvious or signifi-
cant differential effects on the growth of the T-47D or the nontu-
mourigenic MCF-10 lines compared to their Col-0 WT.
In summary, the results obtained for coi1-16B were consistent
with the role of COI1 in the JA signalling pathway. However,
higher expression of the JA receptor in COV99 (B€omer et al.,
2018) did not cause any additional effects. The mutant aos, lack-
ing the positive feedback loop amplification of the JA signal (Park
et al., 2002), showed a less pronounced, although not signifi-
cantly different, effect compared to the WT. In accordance with
the JA-dependency of the observed effects on breast cancer cells,
cev1, which has constitutive JA responses (Ellis & Turner, 2001),
displayed the strongest inhibitory potential.
Fig. 1 The effects of methyljasmonate (MeJA) treatment or co-culture of Arabidopsis jasmonic acid (JA) mutants on human breast cancer cells T-47D and
MDA-MB-361, and on nontumourigenic MCF-10A. (a) Effect of MeJA treatment on the growth of cancer T-47D, MDA-MB-361 or nontumourigenic
MCF-10A cell lines. The data quantified by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay are presented as as relative cell
number (RCN) compared to the vehicle (ethanol) control (). (b) Plants were grown vertically in vitro and photographed at 10 d after sowing (DAS) before
transferring to plates containing media 50 µMMeJA. Plants treated (+) and untreated () were photographed again after 24 h of treatment at 11 DAS
to visualize the rosette phenotype. Bar, 5 mm. (c) At 11 DAS three 3-mm leaf disks were excised and co-incubated in three or four replicate wells with
cancer or nontumourigenic cells for 72 h after which an MTT assay was performed. (d) Effect of the co-incubation of MeJA-treated (+) and untreated ()
plant leaf explants from wild-type (WT) background Col gl1 or JA mutants coi1-16B, aos, COV99 and cev1 on the growth of cancer T-47D, MDA-MB-
361 or nontumourigenic MCF-10A cell lines. The data quantified by MTT assay are presented as RCN of viable cells as a % compared to the growth
control. (a, c) Bars correspond to the mean of at least three independent experiments (error bars denote the SEM). The number of asterisks denote
significance values against the untreated control () of each genotype using two-tailed Student’s t-test: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not
significant. For detailed P-values see Supporting Information Table S2.
 2020 The Authors





Metabolite profiling of human breast cancer T-47D cell
culture media after incubation with Arabidopsis
High-throughput metabolic profiling to investigate the effects of
JAs on Arabidopsis plants in isolation has been performed previ-
ously, albeit in different mutants and experimental conditions,
on leaf intracellular extracts, and multivariate statistical analyses
performed to obtain compound libraries (Cao et al., 2016).
Active compounds from plants need identification and mecha-
nisms of action characterized to assess the full potential of the
bioactives for clinical trials and applications, efficiency and any
adverse effects. The inhibitory effects of MeJA-treated Arabidop-
sis explants on human breast cancer cell growth, encouraged a
search for specialized metabolites using untargeted LC-MS/MS
metabolic profiling. Candidate bioactive MeJA-inducible com-
pounds were predicted to be more abundant in media of MeJA-
treated WT treatments than with coi1-16B. We focussed our
analysis on compounds present in the cell media that could be
recognized by surface receptors. Molecular feature extraction
using MASSPROFILER identified co-eluting isotopes and adducts
comprising 1757 putative features of interest (FOIs) in positive
and negative ion modes (Table S3). Principal component analysis
(PCA) based on the relative abundance of these FOIs showed
clear discrimination between (1) the T-47D and no cell back-
grounds; (2) the Arabidopsis WT and coi1-16B plant leaf disks;
and (3) the MeJA treatment in the Col gl1 samples (Fig. 2a).
Hierarchical clustering of all FOIs based on their normalized
metabolite abundances resulted in well-defined clusters (Fig. 2b).
Distinct metabolite profiles could be detected in the incubation
medium from different treatments. The individual features were
further filtered using predefined conditions (Table 1), identifying
146 FOIs (Fig. 2c) which responded to MeJA in Col gl1 (A1)
more than in coi1-16B (B1) and were likewise abundant in
untreated Col gl1 compared to untreated coi1-16B (C1). These
features fell into clusters 1 and 2 (Fig. 2b) representing com-
pounds affecting the viability of the T-47D cells. Clusters 1 and
2 identified 69 FOIs present or absent in the no T-47D cell con-
trol samples, respectively. Cluster 2 FOIs were COI1-dependent,
MeJA-induced and produced in the Col gl1 WT background
independently of the presence or absence of T-47D cancer cells
and, therefore, plant-derived. By contrast, Cluster 1 FOIs were
COI1-dependent, MeJA-induced and occurred in the Col gl1
WT background, but only in the presence of T-47D cancer cells.
Further filtering (Table 1) identified FOIs MeJA-induced in coi1-
16B (10 FOIs), and those more/less abundant in the T-47D cell
background. These are likely to represent end- or by-products of
T-47D metabolism (117 FOIs), compared to cancer cell media
compounds, metabolized by the T-47D cells (98 FOIs), respec-
tively.
Further analysis identified plant derived Col gl1-specific
MeJA-induced features. All samples, including medium-only and
medium plus T-47D cells were re-aligned and molecular feature
extraction using MASSHUNTER PROFINDER followed by statistical
analysis with MASSPROFILER PROFESSIONAL, performed. This anal-
ysis extracted 161 and 105 putative features in positive and nega-
tive ion mode respectively which were present exclusively in
samples containing leaf discs (Table S4). Of these plant-specific
features, 21 (15 and six in positive and negative ion modes,
respectively) were induced by MeJA in Col gl1 but not in coi1-
16B (Table S4).
Discovery of bioactive metabolites
Accurate mass and isotope composition for the 161 plant-specific
putative features were used to calculate molecular formulas,
search databases and (where present) MS/MS spectra were
extracted. Several identifiable compounds were detected based on
accurate mass and MS/MS spectral matches (Table S5). The
abundance of these compounds was compared in samples con-
taining Arabidopsis WT (Col gl1) or mutant coi1-16B in the
presence or absence of T-47D cells and/or MeJA against media
only (m). As expected, increased JA was detected in MeJA-treated
samples in a COI1-independent manner (Fig. 3). JA presence
was unaffected by the presence of T-47D cells. Of the major spe-
cialized Arabidopsis metabolites, 4-methylsulfinylbutyl isothio-
cyanate (sulforaphane) a breakdown product of the glucosinolate
glucoraphanin (Kissen et al., 2009), and the flavonol glycoside
kaempferol hexoside deoxyhexoside, belonging to one of the
major Arabidopsis flavonoids (Veit & Pauli, 1999), were identi-
fied. Kaempferol glycoside abundance was not affected by MeJA
or by the presence of T-47D cells, and its presence was COI1-in-
dependent. Sulforaphane concentrations were mildly induced by
MeJA in Col gl1, albeit at lower levels in coi-16B, but more
strongly in the presence of T-47D. OPDA, a biosynthetic precur-
sor of JA (Zimmerman & Feng, 1978), was detected. OPDA
accumulated in MeJA-treated samples and at a lower concentra-
tion in coi-16B, but the concentrations were dramatically reduced
in presence of T-47D cells. Of the compounds showing specific
induction by MeJA only in Col gl1, hence COI1-dependent, one
(3 Pos, retention time 10.78 min) (Fig. 3; Tables S4, S5) allowed
preliminary identification. Its abundance was decreased by the
presence of T-47D cells. Its predicted formula C10H9N0/
159.0864 (measured 159.0679, 11 ppm deviation) corresponded
to several candidate compounds, although it was outside the
observed mass accuracy for the other identified compounds and
the umbelliferone internal standard (5 ppm). In the MS/MS
spectrum, 117.06m/z is characteristic of indoles (e.g. indole
acetaldehyde) and quinolines (e.g. 2-methyl-4-hydroxyquinoline
and others).
Further analysis is required to precisely identify the active
ingredients in the complex plant mixture, the compounds
detected in Arabidopsis through this study were potential bioac-
tive compounds.
Incubation with MeJA-treated Arabidopsis altered
transcripts and protein levels of cell cycle regulators in
breast cancer cells
Given that MeJA (Fig. 1a) or MeJA-treated Col gl1 (Fig. 1c)
reduced T-47D cell numbers and that MeJA influences cell cycle
progression (Fig. S1B–E), the effects on cell cycle markers were
investigated.
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We selected the following G1/S specific regulators (Cohen &
Flescher, 2009; Caldon & Musgrove, 2010) and tested their rela-
tive gene expression and protein abundance: Cyclin-dependent
kinase 2 (CDK2, P24941), Cyclin D1 (CCND1, P24385),
Cyclin D3 (CCND3, P30281), Cyclin E1 (CCNE1, P24864),
cell division cycle 6 (CDC6, Q99741), proliferating cell nuclear
antigen (PCNA, P12004), Cyclin-dependent kinase inhibitor 1A
(p21, Cip1, CDKN1A, P38936) and Cyclin-dependent kinase
inhibitor 1B (p27, Kip1, CDKN1B, P46527). Cell cycle progres-
sion through G1/S is mediated by Cyclin D/CDK4 or CDK6
and Cyclin E/CDK2 protein complexes and, once in S phase,
CDC6 and PCNA are essential for DNA replication (Matson &
Cook, 2017). However, p21 and p27 prevent Cyclin/CDK com-
plex formation and participate in DNA damage repair
(Abukhdeir & Park, 2009).
The protein levels of CDC6 and CDK2 in cells in response to
MeJA remained unchanged (Fig. 4a), but the gene expression
levels decreased (Fig. S4). Cyclin D1, Cyclin D3, p27 and PCNA
protein levels mirrored the changes in transcript levels and were
unaffected by MeJA compared to levels in lysates from the mock,
ethanol-treated cells. Cyclin E1 protein levels were reduced and
both p21 transcript and protein levels increased in cells treated
with MeJA, compared to controls (Figs 4a, S4).
When cells were co-incubated with leaf disks from MeJA-
treated plants, protein and transcript levels of CDC6, Cyclin D1
and CDK2 were reduced compared to cells incubated with
untreated leaf disks. Cyclin D3 protein levels also were reduced,
although no differences were observed in transcripts. Co-incuba-
tion with MeJA-treated Col gl1 leaf disks also increased Cyclin
E1, p21 and p27 transcripts, although the effects on protein levels
Fig. 2 Comparative metabolite analysis of Arabidopsis plant leaf disk bioassay. (a) Principal component analysis showing discrimination of T-47D and no
cells background, Arabidopsis wild-type (WT) and coi1-16B plant leaf disks, and methyljasmonate (MeJA) treatment regime, based on metabolite profiles.
(b) The heat map shows normalized abundances of all detected chemical features. Samples and chemical features (putative metabolites) were clustered
based on the Euclidean distances of their normalized metabolite abundances using Ward’s (clustering) algorithm. Sets A1, A2, B1, B2, C1 and C2 show the
chemical features that match (red bars) the conditions of the filtering analysis (A, Col gl1 +MeJA >Col gl1MeJA; B, Col gl1 +MeJA > coi1-16B +MeJA;
C, Col gl1MeJA = coi1-16B MeJA; 1, T-47D background; 2, no cell controls; P = 0.05; see Table 1 for details and number of metabolites meeting the
conditions). (c) Venn diagram of common features matching filtering conditions in T-47D background, where 146 features of interest were identified, most
of which are part of the two highlighted clusters cl1 and cl2 in the heat map. R scripts used to analyze data and to generate the figures are provided as
Supporting Information (Notes S1).
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differed; Cyclin E was increased, p21 was decreased and p27 con-
centrations were unaffected. PCNA protein or transcript levels
were unaffected (Figs 4a, S4).
The effect of MeJA-treated Arabidopsis on the mechanistic
target of rapamycin signalling pathway
The mechanistic target of rapamycin (mTOR) is a known thera-
peutic target in breast cancer (Hare & Harvey, 2017). Recent evi-
dence suggests crosstalk between TOR and JA signalling in
Arabidopsis (Song et al., 2017; Perez-Salamo et al., 2019). For
this reason, the effects of both MeJA and MeJA-treated Col gl1
on mTOR in T-47D breast cancer cells were examined. (Fig. 4b).
Notably, the treatment of T-47D cells with MeJA caused the
opposite effects to those observed with the leaf disks. An increase
in the protein levels of mTOR, p-TOR (Ser2481), p-TOR
(Ser2448), RICTOR, RAPTOR and GbL was observed in
MeJA-treated cells compared to untreated controls. By contrast,
incubation with MeJA-treated Col gl1 did not affect the protein
levels of mTOR and RAPTOR, but decreased the protein abun-
dance of phosphorylated mTORC p-TOR (Ser2448), p-TOR
(Ser2481), RICTOR and GbL in T-47D cells in comparison to
cells incubated with the untreated leaf disks (Fig. 4b).
Overall, these data showed that both MeJA and MeJA-treated
WT Arabidopsis leaves affect mTOR protein levels. When com-
bined with the differences in cell cycle protein data (Fig. 4a), they
indicate that the component(s) involved in mediating the bioac-
tivities on breast cancer cells are likely to be compound(s) or
Fig. 3 Abundance of selected Arabidopsis metabolites identified through MS/MS and database searches. Abundance data (from positive or negative ion
mode) correspond to the peak areas (not normalized) determined by analysis with PROFINDER and MASS PROFILER PROFESSIONAL. The compounds abundance
was compared in samples containing Arabidopsis WT (wild-type, Col Trichome differentiation protein (gl1) or mutant coi1-16B in presence or absence of
T-47D cells and/or methyljasmonate (MeJA) against media only (m). Umbelliferone was used as an internal standard. Values denote averages SD (n = 2/
3).
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downstream metabolite(s) from MeJA-treated leaf explants, dis-
tinct from those induced in T-47D cells by direct treatment with
MeJA (or indeed MeJA itself).
Discussion
A bioassay to assess the effect of methyljasmonate on the
growth of human breast cancer cells
A systematic relationship between the production of plant spe-
cialized metabolites (Balbi & Devoto, 2008; Zhou & Memelink,
2016; Perez-Salamo et al., 2019) and the regulation of growth
and development and response to stress has not yet been estab-
lished. Moreover, Arabidopsis, despite having been used as a
model plant for over 30 yr, has never been considered as a poten-
tial source of phytotherapeutics.
Jasmonates (JAs) elicit de novo transcription and translation and,
ultimately, the biosynthesis of specialized metabolites in plants
(Memelink et al., 2001). The anticancer activity of JAs has been
demonstrated both in vitro and in vivo (Fingrut & Flescher, 2002;
Flescher, 2005; Balbi & Devoto, 2008; Cesari et al., 2014; Perez-
Salamo et al., 2019). However, it is not known whether this is a
direct effect of JAs. Induction of specialized metabolites could
underlie the increased growth inhibition of human breast cancer
cells when co-incubated with methyljasmonate (MeJA)-treated
plant samples. The effectiveness of compounds from plants also
could be affected by interaction between them and the target cells.
To our knowledge, there has been no systematic study comparing
the effect of JAs on breast cancer and nontumourigenic breast cells.
We show that the direct cytotoxic effect of MeJA is selective
for human breast cancer cells (Figs 1a, S1). Previous studies have
reported low or no cytotoxicity of JAs to healthy cells compared
to cancer cells (Fingrut & Flescher, 2002; Rotem et al., 2003;
Reischer et al., 2007). Cytotoxicity assays (Yeruva et al., 2008)
showed a significant decrease in the cell viability of the human
breast cancer cell lines MDA-MB-435 and MCF-7 at concentra-
tions of ≥ 1.5 mMMeJA.
In our study, Arabidopsis explants treated with 50 µM MeJA
had an effect on breast cancer cells (Fig. 1d) comparable to treat-
ment with mM concentrations of MeJA. Such enhanced efficacy
could be indicative of synergic effects of JAs with other com-
pounds. The reduced sensitivity of MDA-MB-361 compared to
T-47D cells, could be attributable to their HER2 positivity,
linked to recalcitrance to chemotherapy (Sauter et al., 2009).
This difference emphasizes the usefulness of our bioassay to
detect differences between treatments and cell types, and to detect
the interactions between phytotherapeutics and cancer cells.
Coronatine-insensitive protein 1-dependent jasmonic acid
signalling mediates the effect of exogenous MeJA
treatment of Arabidopsis explants on reducing human
breast cancer cells growth
Suppression of cancer cell growth was consistently stronger when
cells were co-incubated with MeJA-treated plant samples com-
pared to untreated controls (Fig. 1d). The differential effect
between MeJA-treated and untreated plant samples was due to
jasmonic acid (JA) signalling. This finding indicated that anti-
cancer activity was not only a direct effect of MeJA itself, but also
the result of production of JA-regulated, Coronatine-insensitive
protein 1 (COI1)-dependent specialized metabolites (Devoto
et al., 2005; Pauwels et al., 2008; Perez-Salamo et al., 2019).
Overexpression of COI1 was found previously to affect posi-
tively the availability of metabolites such as b-alanine, threonic
Fig. 4 Cell cycle regulators and components of the mechanistic target of rampamycin (mTOR) signalling pathway are altered in breast cancer cells upon
methyljasmonate (MeJA) treatment or incubation with Col Trichome differentiation protein (gl1) leaf disks. T-47D cells were subjected to 2mM
methyljasmonate (MeJA) or co-incubated with excised leaf disks of Colgl1 seedlings treated (+) or untreated () with MeJA for 72 h and proteinlevels
analysed. (a) Western blot detection of cell division cycle 6 (CDC6), Cyclin E1 (CYCE1), CyclinD1, CyclinD3, proliferating cell nuclear antigen (PCN),
Cyclin-dependent kinase 2 (CDK2), Cyclin-dependent kinase inhibitor 1A (p21) and 1B (p27), in T-47D cells. b-Actin proteinlevels and Ponceau-S staining
were used as to determine equal loading. (b) Western blot detection of mTOR, p-TOR Ser2481, p-TOR Ser2448, RICTOR, RAPTOR and GbL in T-47D
cells using the indicated antibodies. Samples were harvested after 72 h treatment, along with a vehicle-treated growth control (mock). b-Actin
proteinlevels and Ponceau-S staining were used to determine equal loading.
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acid, putrescine, glucose and myo-inositol, thereby providing a
connection between JA-inhibited growth and stress responses
(B€omer et al., 2018). Here, COV99 plants overexpressing the
COI1 receptor, exhibit wild-type (WT) responses in bioassays,
indicating that any observed increases in inhibition of cancer cell
growth by MeJA-treatment of Arabidopsis do not necessarily
depend on the dose of the COI1 receptor.
The differential effects of MeJA treated and untreated leaf
samples were consistently less pronounced in aos compared to the
corresponding WT Col Trichome differentiation protein (gl1),
indicating that the positive feedback regulatory loop and endoge-
nous JA concentrations may contribute to the anticancer poten-
tial of MeJA-treated Arabidopsis. In accordance with the JA-
dependency of the effects on the breast cancer cells, explants of
cev1 displayed the strongest inhibitory potential on the growth of
T-47D and MDA-MB-361 breast cancer cells. Higher endoge-
nous concentrations of JAs and constitutive JA responses in the
cev1 mutant (Ellis & Turner, 2001) emphasize the role of JA-in-
duced specialized metabolites in breast cancer cell growth sup-
pression. The enhanced efficacy of the MeJA-treated samples in
inhibiting the growth of breast cancer cells also could be indica-
tive of a synergistic effect between JAs and the production of
other plant-derived compounds with anticancer activity.
Notably, cell growth of the nontumourigenic MCF-10A cells was
not affected significantly following exposure to leaf disks, except
for exposure to MeJA-treated cev1 explants. The inhibitory
potential of untreated Arabidopsis leaf disks and leaf disks from
MeJA-treated plants is likely, and therefore selective, for cancer
cells, demonstrating a similar selective cytotoxicity towards
cancer cells as previously described for MeJA.
Identification of Arabidopsis metabolites inhibiting breast
cancer cell growth
Untargeted LC-MS/MS identified COI1-dependent and MeJA-
induced compounds in the cell media, in the presence and
absence of T-47D cells (Fig. 2; Table 1). This analysis indicated
complex interactions between Arabidopsis metabolites and T-
47D cells. Two hundred and sixty-six plant-specific MeJA-in-
duced features were detected (Table S4) and some putatively
identified, based on accurate mass and MS/MS spectral matches,
lending confidence to our conclusion that other compounds are
unknowns and awaiting discovery (Fig. 3; Table S5). The uni-
form abundance of the plant-specific flavonol glycoside,
kaempferol hexoside deoxyhexoside, across all samples (Veit &
Pauli, 1999) validated compounds changes under varying condi-
tions. The identification of JA in MeJA-treated samples also vali-
dated our ability to identify possible breakdown products of
MeJA and/or to detect endogenous JAs inhibiting breast cancer
cell growth.
One explanation for the complex cis-(+)-12-oxophytodienoic
acid (OPDA) abundance pattern, induced in MeJA-treated sam-
ples and decreased in the presence of T-47D cells, is that MeJA
inhibits endogenous JA synthesis in leaves, resulting in OPDA
accumulation and secretion. Because there are four possible
stereoisomers of OPDA in plants (Schaller et al., 1998), it is
possible that that MeJA induces accumulation of a specific one.
Unfortunately, the chromatography column used for LC-MS is
unable to resolve these stereoisomers. However, the T-47D cells
might metabolize OPDA (or inhibit its secretion). Our data sup-
port OPDA induction of JA-independent specialized metabolite
production (Taki et al., 2005) and that direct treatment with
OPDA has anticancer activity by targeting Cyclin D1 (Nedret
et al., 2008). Significantly, we showed that OPDA is produced
by the plants and that it may cause a reduction in the Cyclin D1
protein levels (Fig. 4a).
Although glucosinolates, including sulforaphane, act as anti-
cancer compounds (Mokhtari et al., 2018), isothiocyanates
derived from glucosinolates do not play a major role in growth
suppression of the human breast cancer cells (Fig. S3; Table S2).
The possible identification of a plant-specific MeJA-induced
compound with an MS/MS spectrum characteristic of indoles
and quinolines provides possible mechanistic insights into the
effects of MeJA in plants. Importantly both classes of compounds
have been previously identified as anticancer (Musiol, 2017) but
their mechanisms of actions remained elusive.
D-type Cyclins, Cell division cycle 6 and Cyclin-dependent
kinase 2 are mechanistic targets of MeJA-induced
Arabidopsis bioactivities
The effect on the growth of breast cancer cells caused by MeJA-
treated plants, and by direct MeJA treatment (Figs 1, S2, S3),
prompted our investigation of cell cycle markers in T-47D cells,
under both conditions, whereby strikingly differential effects
were detected (Figs 4, S4). Our data suggest that JAs delay the
progression of cells from G0/G1 phase into S phase inducing
apoptosis (Fig. S1C,D). Stalling the cells in G0/G1 may gain
time to repair cellular damage. At high doses of MeJA, irreparable
damage induced cell death. Likewise, efforts to increase G2-M
arrest have been associated with enhanced apoptosis (Ehrlichova
et al., 2005).
The action of D- and E-type Cyclins, Cyclin-dependent kinase
2 (CDK2) and the CDK inhibitor proteins p21, p27 and p57
characterize the G1 phase of the cell cycle and activation of target
proteins for S-phase progression (Caldon & Musgrove, 2010).
p27 and p21 inhibit Cyclin CDK complexes in G0/G1. It has
been hypothesised that PCNA downregulation induces cell cycle
arrest, in association with Cyclin D1 or D3, CDK2 and p21
(Cohen & Flescher, 2009). Lack of detectable changes in expres-
sion of either p27 and PCNA in our study suggests cell type-
specific regulation of the cell cycle either by MeJA or by MeJA-
treated leaf explants. The relative stability of p27 could also be a
positive indicator of better patient outcome following MeJA
treatment (Alkarain et al., 2004).
Methyljasmonate treatment reduced Cyclin E1 (CYCE1) and
increased p21 protein levels (Fig. 4a), supporting our cell cycle
analysis (Fig. 4a). E-type Cyclin activity is limiting for cells pass-
ing from G1 into S-phase. Cyclin E binds and activates CDK2
leading to S-phase specific gene expression (M€or€oy & Geisen,
2004). CDK2 also phosphorylates several components of the
DNA pre-replication complex, including cell division cycle 6
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(CDC6) (Chuang et al., 2009). The reduction of CYCE1 and
increased p21 protein levels (Figs 4a, 5), also supports the flow
cytometry analysis. A different effect was observed for MeJA-
treated plants on CYCE1 and p21, highlighting the mechanistic
differences between the direct effects of MeJA treatment of the
breast cancer cells and incubation with MeJA-treated plant
explants.
Downregulation of CDK2 gene expression was observed fol-
lowing incubation with both MeJA and MeJA-treated leaf disks
(Fig. S4), although only the latter caused reduction of CDK2
protein (Figs 4a, 5). This suggests that incubation with MeJA-
treated plant explants, but not with MeJA, activate additional sig-
nalling pathways leading to CDK2 protein degradation. The
association of ubiquitin-dependent degradation of CDK2 with
the arrest of tumour growth in acute myeloid leukemia (AML)
cells (Ying et al., 2018) supports this hypothesis.
D-type Cyclins (D1, D2 and D3) are essential for G1 phase
and can limit G1/S transition (Herzinger & Reed, 1998). Our
results confirmed that MeJA treatment of human breast cancer
cell lines had no effect on Cyclin D1 expression at the RNA level
as reported for neuroblastoma cells by Tong et al., (2008). Strik-
ingly, we also showed that MeJA-treated Arabidopsis explants
substantially reduced the levels of Cyclin D proteins in human
breast cancer cell lines, in accordance with studies linking the
downregulation of Cyclin D1 and Cyclin D3 levels to antitu-
mour therapy in breast cancer patients (Ortiz et al., 2017; Wang
et al., 2019), hereby providing mechanistic targets for MeJA-in-
duced plant bioactivities inhibiting breast cancer cells growth,
and further ground for these cell cycle regulators as targets of
anticancer compounds.
The mammalian CDC6 is a trifunctional AAA + ATPase
(Duderstadt & Berger, 2008), controlling the G1/S transition,
DNA replication and cell survival (Okayama, 2012). CDC6 also
controls CDK2 activity during G1/S transition and subsequent
obstruction of apoptosome assembly inhibiting cell death during
proliferating (Niimi et al., 2012). In our study, the levels of
CDC6 protein were dramatically reduced by MeJA-treated
plants, supporting previous findings where CDC6 was identified
as target for radiosensitivity in nasopharyngeal carcinoma (Li
et al., 2016). CDC6 downregulation shares similarity with the
effect of MeJA treatment on Arabidopsis that we demonstrated
previously (Noir et al., 2013). JAs-induced effects, common to
both mammalian and plant cells following JA treatment, include
the suppression of cell proliferation, reactive oxygen species gen-
eration, cell death induction, heat shock protein expression and
mitogen-activated protein kinase induction (Flescher, 2007;
Balbi & Devoto, 2008; Cesari et al., 2014; Perez-Salamo et al.,
2019). The list of common effects can be therefore extended to
Fig. 5 Differential regulation of breast cancer cell growth by methyljasmonate (MeJA) or MeJA-treated leaf disks. Treatments with MeJA (left) or MeJA-
treated leaf disks (right) on breast cancer cells alter proteinlevels of different core cell cycle regulators and the mechanistic target of rampamycin (mTOR)
pathway, resulting in tumour growth inhibition. MeJA treatment induces changes in Cyclin-dependent kinase inhibitor 1A (p21) and Cyclin E1 (CYCE1)
levels, while inducing the accumulation of the components of both mTORC1 and mTORC2 complexes. By contrast, incubation with MeJA-treated leaf
disks not only affects cell division cycle 6 (CDC6), Cyclin-dependent kinase 2 (CDK2), Cyclin E1 (CYCE1), CyclinD1, CyclinD3 and Cyclin-dependent kinase
inhibitor 1A (p21), but also inhibits the accumulation of the mTORC2 complex. Names and 2D structures (PubChem) of compounds discovered through
MS/MS are indicated. Red and green shapes indicate accumulation or reduction in proteinlevels, respectively.
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reduction in CDC6 activity, a key component in JAs-suppressed
growth in both plant and cancer cells.
The inhibition of the mTORC2 complex is a target for
MeJA-induced plant bioactivities
In breast cancer cells, treatment with Palbociclib, a CDK4/6
inhibitor, upregulates mechanistic target of rapamycin (mTOR)
whilst promoting G0/G1 cell cycle arrest (Cretella et al., 2018).
Cell cycle arrest in the presence of active mTOR promotes senes-
cence and geroconversion, but the inhibition of mTOR with
rapamycin partially suppresses the senescent phenotype (Leon-
tieva & Blagosklonny, 2013). In our study, different effects were
caused by MeJA treatment alone and by incubation with MeJA-
treated plant explants. It is surprising that, upon MeJA treatment,
mTORC1/2 protein levels increased, whereas incubation with
MeJA-treated leaf disks decreased the protein levels of the
mTORC2 component Rictor (Figs 4b, 5), highlighting mecha-
nistic differences between the two treatments. The mTORC1
complex senses nutrient status to regulate protein and lipid
biosynthesis, stimulating cell growth. The mTORC2 complex
also responds to growth factors, as well as regulating the actin
cytoskeleton, ion transport, and cell growth and survival (Jacinto
et al., 2004). Our findings indicate that inhibition of the
mTORC2 complex is the mechanism for MeJA-induced plant
bioactivities blocking breast cancer cells growth.
In Arabidopsis, in response to positive mitogenic signals, such
as light, sugar availability and hormones, the TOR signalling
pathway promotes cell growth that connects to the entry and cell
division cycle via multiple signalling (Henriques et al., 2014;
Ahmad et al., 2019). Yet there is no evidence of crosstalk between
the effects of JAs and mTOR signalling in mammalian cells.
However, in plants, mTOR is known to regulate phytohormone
synthesis, as well as JAs signalling (Song et al., 2017; Perez-
Salamo et al., 2019), whereby crosstalk contributes to the trade-
off between growth and defence, by modulating JA signalling
and biosynthesis regulating growth conditions (Song et al., 2017;
Perez-Salamo et al., 2019).
Our study ascribes separate roles for MeJA and MeJA-derived
compounds from Arabidopsis impacting mTOR in the breast
cancer cell cycle. It is striking that conserved crosstalk between
mTOR and JAs occurs in different kingdoms in regulating the
cell cycle. Further studies of these naturally occurring plant com-
pounds will be important for improving our understanding of
checkpoint modulation and potentially to develop novel clinical
approaches to the treatment of human cancers.
Conclusions
Our findings ascribe unprecedented medicinal properties to what
has been considered, so far, a model plant: Arabidopsis. By study-
ing the signalling in cancer cells, we discovered universally con-
served modes of action of JAs between plant and animal cells.
Overall, in our study, a synergistic effect by MeJA and by com-
pounds induced by it on the cell cycle associates with the
decreased levels of CDC6, CDK2, Cyclin D1 and Cyclin D3
(Fig. 5). Consequently, the downregulation of these cell cycle reg-
ulators could mediate the mechanism behind the reduction in
breast cancer cell viability. Strikingly for future applications in
cancer therapy, the action of MeJA and compounds upregulated
in the Arabidopsis metabolome, target a central pivot of the
highly complex mechanism controlling cell proliferation and sur-
vival. Whether the effect on cell cycle markers depends on
mTOR, or on the activation of the latter by MeJA as a down-
stream cellular response, remains to be demonstrated.
The present study provides a new platform for the discovery of
plant-derived, bioactive compounds within complex plant mix-
tures while also allowing the identification of synergistic effects
between phytochemicals and target cells. Most traditional
chemotherapeutic agents are nonspecific but selective as they act
by killing cells that divide rapidly, which is one of the main prop-
erties of most cancer cells. We validated the reproducibility of the
system by undertaking assays with healthy epithelial cells; show-
ing that MeJA-treated Arabidopsis explants are effective in selec-
tively modulating the proliferation of tumourigenic compared to
nontumourigenic cells and discriminating between them.
The bioassay allowed production of high-value chemicals in
sufficient quantities to be detected by LC-MS even from plants
with no known medicinal pedigree, allowing untapped resources
to be mined without a priori assumptions. The system has the
potential to be adapted to identify different classes of bioactive
phytochemicals. Different plants can be tested allowing direct
comparison of known medicinal plants with new ones with
unrecognized effects; different cell types could be used to define
the specificity of bioactive phytochemicals and assays could be
calibrated with the combined use of mutants or phytochemical
inducers. The analysis of the metabolome within targets cells also
could be performed to gain further insights into the absorption
mechanisms. This study has important implications for the iden-
tificatino of metabolites with anticancer bioactivities and it will
have applications in developing treatments for other diseases.
Combined with recent progress in metabolic engineering and
biotechnology, our approach will also facilitate production and
analysis of bioactivities of valuable metabolites from plants at
industrial scales.
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